Press Release

Peptide Antibiotics Market to grow with a CAGR of 6.35%

Increasing healthcare infrastructure and a supportive regulatory environment are the major drivers for the Global Peptide Antibiotics Market.

 

According to TechSci Research report, “Global Peptide Antibiotics Market Industry Size, Share, Trends, Competition, Opportunity and Forecast, 2018-2028”, Global Peptide Antibiotics Market has valued at USD 4.90 billion in 2022 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 6.35% through 2028. This can be due to collaborations and partnerships among leading companies with a diverse approach to merge the expertise of individual companies and to strengthen their position in the market.

 Antibiotic stewardship programs play a crucial role in shaping the demand for peptide antibiotics and antibiotics in general. These programs are implemented in healthcare settings to promote responsible and judicious use of antibiotics. While antibiotic stewardship programs are primarily aimed at optimizing antibiotic use and curbing the rise of antibiotic resistance, they can indirectly influence the demand for specific types of antibiotics like peptide antibiotics. Antibiotic stewardship programs emphasize the importance of selecting the most appropriate antibiotic for a given infection. Peptide antibiotics, with their specific mechanisms of action and limited spectrum of activity, can be valuable in achieving targeted therapy. When stewardship programs recommend or require the use of specific antibiotics based on microbial susceptibility testing, peptide antibiotics may be chosen if they are effective against the identified pathogen. One key objective of antibiotic stewardship is to reduce the unnecessary use of broad-spectrum antibiotics, which can contribute to antibiotic resistance. Peptide antibiotics, often having a narrower spectrum of activity, can be preferred in cases where a more targeted approach is appropriate.

 

Browse over XX market data Figures and spread through 110 Pages and an in-depth TOC on "Peptide Antibiotics Market

 

Peptide antibiotics are anti-infective and anti-tumor medications that contain polypeptide chains. The two types of peptide antibiotics are those produced by ribosomal synthesis and those produced by non-ribosomal synthesis. The benefits of peptide antibiotics include their high specificity, high efficacy, and low toxicity.

In September 2021, to produce Daptomycin for injection to treat severe bacterial infections, such as skin and soft tissue infections, bloodstream infections, and endocarditis, AuroMedics Pharma LLC stated that it has gained permission from the USFDA. Under the trade name Cubicin, daptomycin is a lipopeptide antibiotic that is given intravenously. It displaces the bacterial cell membrane to function. Gramicidin, which is often created in conjunction with other antibiotics, shares a similar mechanism. With the caveat that oral use of this medication may be harmful, it is an antibacterial agent for the topical treatment of skin infections. This medication has a significant deal of potential as a treatment for renal cell carcinoma, the most frequent kind of kidney cancer in people, according to in vitro and in vivo research.

 Patient adherence is a significant challenge in the global peptide antibiotics market, as it is in healthcare more broadly. Patient adherence refers to a patient's ability and willingness to follow prescribed treatment plans, including taking medications as directed by healthcare providers. Some peptide antibiotics may have complex dosing regimens, requiring patients to take multiple doses at specific times or with certain conditions (e.g., with or without food). These complexities can lead to confusion and non-adherence. The frequency of administration can vary among peptide antibiotics. Some may require multiple daily doses, while others are administered less frequently. Frequent dosing can be burdensome for patients, leading to missed doses. The duration of treatment with peptide antibiotics can vary depending on the type and severity of the infection. Longer treatment courses may increase the likelihood of non-adherence, as patients may discontinue treatment prematurely.

Global Peptide Antibiotics Market segmentation is based on Type, Route of Administration, Distribution Channel, Region and Company

Based on Type, Global Peptide Antibiotics Market is segmented into Non-Ribosomal Synthesized Peptide Antibiotics, Ribosomal Synthesized Peptide Antibiotics. Ribosomal synthesized peptide antibiotics are a class of antibiotics that are produced by ribosomes, cellular structures responsible for protein synthesis, within living organisms. These antibiotics are synthesized through ribosomal machinery in response to specific genetic instructions encoded in the organism's DNA. Ribosomal synthesized peptide antibiotics are naturally occurring compounds that originate from living organisms such as bacteria, fungi, and plants. They are a product of the organism's own metabolic processes. These antibiotics exhibit structural diversity and can vary significantly in size and complexity. They are composed of amino acids, the building blocks of proteins, arranged in specific sequences. Ribosomal synthesized peptide antibiotics are produced within the ribosomes of the organism. Ribosomes read the genetic code in the organism's DNA and translate it into a sequence of amino acids, forming the peptide antibiotic.

Based on Region, North America dominated the Global Peptide Antibiotics Market. North America often hosts a significant number of clinical trials, including those for new antibiotics. The availability of a diverse patient population and experienced research centers makes it an attractive location for conducting clinical research. The region has been actively addressing antibiotic resistance concerns, leading to a focus on the development of new antibiotics, including peptides, to combat drug-resistant bacteria. The availability of venture capital, private equity, and funding opportunities for pharmaceutical and biotechnology startups in North America supports the research and development of novel antibiotics. The presence of well-established pharmaceutical companies, biotech startups, and academic research institutions in North America fosters competition and innovation in the field of peptide antibiotics.

Asia-pacific region to fastest growth in the Global Peptide Antibiotics Market. Many countries in the Asia-Pacific region have been increasing their healthcare expenditure to improve healthcare infrastructure and access to medical services. This includes investments in research and development, which can boost the development and adoption of peptide antibiotics. The Asia-Pacific region is home to a significant and rapidly aging population. Older adults are more susceptible to infections, driving the demand for antibiotics, including peptide antibiotics, to treat age-related health issues and infections. Several emerging economies in Asia, such as China and India, have been experiencing robust economic growth. This growth has led to increased healthcare spending, improved healthcare access, and greater demand for advanced medical treatments.

 

Some of the major companies operating in the Global Peptide Antibiotics Market include:

  • Pfizer Inc.
  • Merck & Co., Inc.
  • AbbVie Inc
  • GSK Group of Companies
  • Sandoz International GmbH
  • Novartis AG
  • Xellia Pharmaceuticals
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • AuroMedics Pharma LLC

 

 

Download Free Sample Report

Customers can also request 10% free customization on this report

 

“Certain areas, particularly in North America, are projected to exert significant demand for peptides. The growth in the competitive landscape and the presence of well-established companies in the market, committed to enhance the overall wellbeing of people each year, are expected to contribute to a remarkable growth of the Global Peptide Antibiotics Market in the forecast period," said Mr. Karan Chechi, Research Director with TechSci Research, a research-based Global management consulting firm.

Peptide Antibiotics Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented by Type (Non-Ribosomal Synthesized Peptide Antibiotics, Ribosomal Synthesized Peptide Antibiotics), by Route of Administration (Injectable, Oral, Topical), by Distribution Channel (Hospital Pharmacy, Online Pharmacy & Retail Pharmacy), by region, and Competition evaluated the future growth potential of Global Peptide Antibiotics Market and provides statistics & information on market size, structure, and future market growth. The report intends to provide innovative market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Peptide Antibiotics Market.

 

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York 10017

Tel: +1-646-360-1656

Email: [email protected]

Website: www.techsciresearch.com

Relevant News